Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone

Details for Australian Patent Application No. 2005321826 (hide)

International Classifications

Event Publications

3 May 2007 PCT application entered the National Phase

PCT publication WO2006/072093 Priority application(s): WO2006/072093

11 February 2010 Amendment Made

The nature of the amendment is: Amend the applicant name from DOR BioPharma, Inc. to Soligenix, Inc. 2006

15 March 2012 Application Accepted

Published as AU-B-2005321826

12 July 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.